A detailed history of Huntington National Bank transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Huntington National Bank holds 1,376 shares of CPRX stock, worth $31,895. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,376
Previous 1,433 3.98%
Holding current value
$31,895
Previous $31,000 12.9%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025

SELL
$19.13 - $22.22 $1,090 - $1,266
-57 Reduced 3.98%
1,376 $27,000
Q2 2025

Aug 05, 2025

BUY
$21.4 - $26.31 $15,707 - $19,311
734 Added 105.01%
1,433 $31,000
Q1 2025

May 14, 2025

BUY
$19.53 - $25.74 $10,917 - $14,388
559 Added 399.29%
699 $16,000
Q4 2024

Feb 12, 2025

BUY
$19.73 - $23.93 $631 - $765
32 Added 29.63%
140 $2,000
Q2 2024

Aug 08, 2024

BUY
$14.68 - $16.92 $264 - $304
18 Added 20.0%
108 $1,000
Q2 2023

Aug 11, 2023

BUY
$11.5 - $18.08 $1,035 - $1,627
90 New
90 $1,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.38B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Huntington National Bank Portfolio

Follow Huntington National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Huntington National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Huntington National Bank with notifications on news.